• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤临床试验设计:综述。

Design of oncology clinical trials: a review.

机构信息

3 Everett Street, #3, Cambridge, MA 02138, USA.

出版信息

Crit Rev Oncol Hematol. 2013 Oct;88(1):144-53. doi: 10.1016/j.critrevonc.2013.03.007. Epub 2013 Apr 25.

DOI:10.1016/j.critrevonc.2013.03.007
PMID:23623356
Abstract

Cancer is a disease that occurs due to the uncontrolled multiplication of cells that invade nearby tissues and can spread to other parts of the body. An increased incidence of cancer in the world has led to an increase in oncology research and in the number of oncology trials. Well designed oncology clinical trials are a key part of developing effective anti-cancer drugs. This review focuses on statistical considerations in the design and analysis of oncology clinical trials.

摘要

癌症是一种由于细胞失控增殖而发生的疾病,这些细胞会侵袭附近的组织,并可能扩散到身体的其他部位。全球癌症发病率的增加导致了肿瘤学研究和肿瘤试验数量的增加。精心设计的肿瘤学临床试验是开发有效抗癌药物的关键部分。本文综述了肿瘤学临床试验设计和分析中的统计学考虑因素。

相似文献

1
Design of oncology clinical trials: a review.肿瘤临床试验设计:综述。
Crit Rev Oncol Hematol. 2013 Oct;88(1):144-53. doi: 10.1016/j.critrevonc.2013.03.007. Epub 2013 Apr 25.
2
Clinical trial design in metastatic breast cancer: a commentary.转移性乳腺癌的临床试验设计:一篇评论
Can J Oncol. 1995 Dec;5 Suppl 1:40-2.
3
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.一种用于肿瘤学试验的适应性无缝II/III期设计,该设计使用相关生存终点进行亚组选择。
Pharm Stat. 2011 Jul-Aug;10(4):347-56. doi: 10.1002/pst.472. Epub 2010 Dec 8.
4
Lessons learned from independent central review.独立中央审查的经验教训。
Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.
5
Improving the design of phase II trials of cytostatic anticancer agents.改进细胞抑制性抗癌药物II期试验的设计。
Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14.
6
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.新型靶向治疗的临床试验:终点指标、试验设计与分析。
Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057.
7
Statistical considerations for the next generation of clinical trials.下一代临床试验的统计学考虑。
Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014.
8
Genomic Alteration-Driven Clinical Trial Designs in Oncology.肿瘤学中基于基因组改变的临床试验设计。
Ann Intern Med. 2016 Aug 16;165(4):270-8. doi: 10.7326/M15-2413. Epub 2016 May 24.
9
Optimal and minimax three-stage designs for phase II oncology clinical trials.肿瘤学II期临床试验的最优和极小极大三阶段设计。
Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6.
10
Phase II clinical trials in oncology: strengths and limitations of two-stage designs.肿瘤学中的II期临床试验:两阶段设计的优势与局限性
Cancer Invest. 2006 Jun-Jul;24(4):404-12. doi: 10.1080/07357900600705516.

引用本文的文献

1
The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology.病理学家在癌症生物标志物驱动的临床试验设计与实施中的作用:欧洲病理学会立场文件
Virchows Arch. 2025 Feb;486(2):207-214. doi: 10.1007/s00428-024-04005-1. Epub 2024 Dec 17.
2
A class of two-sample nonparametric statistics for binary and time-to-event outcomes.一类用于二项和生存数据的两样本非参数统计方法。
Stat Methods Med Res. 2022 Feb;31(2):225-239. doi: 10.1177/09622802211048030. Epub 2021 Dec 6.
3
A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.
临床药物试验中肿瘤成像的 RECIST 1.1 指南
Radiol Imaging Cancer. 2021 May;3(3):e210008. doi: 10.1148/rycan.2021210008.
4
Design and Conduct Considerations for First-in-Human Trials.首次人体试验的设计和实施考虑因素。
Clin Transl Sci. 2019 Jan;12(1):6-19. doi: 10.1111/cts.12582. Epub 2018 Aug 24.
5
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.生物标志物引导的II期和III期非适应性试验设计:方法学综述
J Pers Med. 2017 Jan 25;7(1):1. doi: 10.3390/jpm7010001.
6
An analysis of common ethical justifications for compassionate use programs for experimental drugs.对实验性药物同情用药项目常见伦理依据的分析。
BMC Med Ethics. 2016 Oct 18;17(1):60. doi: 10.1186/s12910-016-0145-x.
7
Pragmatic medicine in solid cancer: a translational alternative to precision medicine.实体癌中的实用医学:精准医学的一种转化替代方案。
Onco Targets Ther. 2016 Apr 5;9:1839-55. doi: 10.2147/OTT.S103832. eCollection 2016.
8
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.二、三期生物标志物引导的适应性试验设计:方法学综述
PLoS One. 2016 Feb 24;11(2):e0149803. doi: 10.1371/journal.pone.0149803. eCollection 2016.
9
Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.通过分析ClinicalTrials.gov上的临床试验数据来探讨肿瘤学中联合药物治疗的特点。
Pac Symp Biocomput. 2015:68-79.